CD22 modulation alleviates amyloid β-induced neuroinflammation

Abstract Neuroinflammation is a crucial driver of multiple neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Yet, therapeutic targets for neurodegenerative diseases based on neuroinflammation still warrant investigation....

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Dong Mai, Qingqing Zhang, Cheuk Lim Fung, Shui On Leung, Chi Ho Chong
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Journal of Neuroinflammation
Subjects:
Online Access:https://doi.org/10.1186/s12974-025-03361-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823861708151586816
author Yu Dong Mai
Qingqing Zhang
Cheuk Lim Fung
Shui On Leung
Chi Ho Chong
author_facet Yu Dong Mai
Qingqing Zhang
Cheuk Lim Fung
Shui On Leung
Chi Ho Chong
author_sort Yu Dong Mai
collection DOAJ
description Abstract Neuroinflammation is a crucial driver of multiple neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Yet, therapeutic targets for neurodegenerative diseases based on neuroinflammation still warrant investigation. CD22 has been implicated in neuroinflammatory diseases, namely AD. Specifically, plasma soluble CD22 (sCD22) level is upregulated in patients with AD. Direct experimental evidence for the role of CD22 in neuroinflammation is needed, as is a better understanding of its impact on microglia activation and therapeutic potential. Here we reported that sCD22 promotes neuroinflammation both in vivo and in vitro. sCD22 activated microglia via both p38 and ERK1/2 signaling pathway for the secretion of TNFα, IL-6 and CCL3. Moreover, sCD22 activated microglia via sialic acid binding domain and 2,6 linked sialic acid glycan on sCD22. The pivotal therapeutic potential of targeting CD22 was demonstrated in Amyloid β (Aβ) induced-neuroinflammation in hCD22 transgenic mice. Suciraslimab improved working memory and resolved neuroinflammation in vivo. Further, membrane CD22 inhibited Amyloid β (Aβ) induced-NFκB signaling pathway and mechanistic study delineated that suciraslimab suppressed Aβ-induced IL-1β secretion in human microglia and PBMC. Suciraslimab also suppressed IL-12 and IL-23 secretion in human PBMC. Moreover, suciraslimab reduced the surface expression of α4 integrin on B cells. Intriguingly, we discovered that CD22 interact with Aβ and suciraslimab enhanced internalization of CD22-Aβ complex in microglia. Our data highlights the importance of sCD22 in driving neuroinflammation and the dual mechanism of targeting CD22 to resolve Aβ-induced inflammation and promote Aβ phagocytosis.
format Article
id doaj-art-2ddef2e10272401d84de0efcefc7dfb9
institution Kabale University
issn 1742-2094
language English
publishDate 2025-02-01
publisher BMC
record_format Article
series Journal of Neuroinflammation
spelling doaj-art-2ddef2e10272401d84de0efcefc7dfb92025-02-09T12:48:12ZengBMCJournal of Neuroinflammation1742-20942025-02-0122111910.1186/s12974-025-03361-2CD22 modulation alleviates amyloid β-induced neuroinflammationYu Dong Mai0Qingqing Zhang1Cheuk Lim Fung2Shui On Leung3Chi Ho Chong4SinoMab BioScience LimitedStem Cell & Regenerative Medicine Consortium, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong KongSinoMab BioScience LimitedSinoMab BioScience LimitedSinoMab BioScience LimitedAbstract Neuroinflammation is a crucial driver of multiple neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Yet, therapeutic targets for neurodegenerative diseases based on neuroinflammation still warrant investigation. CD22 has been implicated in neuroinflammatory diseases, namely AD. Specifically, plasma soluble CD22 (sCD22) level is upregulated in patients with AD. Direct experimental evidence for the role of CD22 in neuroinflammation is needed, as is a better understanding of its impact on microglia activation and therapeutic potential. Here we reported that sCD22 promotes neuroinflammation both in vivo and in vitro. sCD22 activated microglia via both p38 and ERK1/2 signaling pathway for the secretion of TNFα, IL-6 and CCL3. Moreover, sCD22 activated microglia via sialic acid binding domain and 2,6 linked sialic acid glycan on sCD22. The pivotal therapeutic potential of targeting CD22 was demonstrated in Amyloid β (Aβ) induced-neuroinflammation in hCD22 transgenic mice. Suciraslimab improved working memory and resolved neuroinflammation in vivo. Further, membrane CD22 inhibited Amyloid β (Aβ) induced-NFκB signaling pathway and mechanistic study delineated that suciraslimab suppressed Aβ-induced IL-1β secretion in human microglia and PBMC. Suciraslimab also suppressed IL-12 and IL-23 secretion in human PBMC. Moreover, suciraslimab reduced the surface expression of α4 integrin on B cells. Intriguingly, we discovered that CD22 interact with Aβ and suciraslimab enhanced internalization of CD22-Aβ complex in microglia. Our data highlights the importance of sCD22 in driving neuroinflammation and the dual mechanism of targeting CD22 to resolve Aβ-induced inflammation and promote Aβ phagocytosis.https://doi.org/10.1186/s12974-025-03361-2CD22NeuroinflammationAmyloid βAlzheimer’s disease
spellingShingle Yu Dong Mai
Qingqing Zhang
Cheuk Lim Fung
Shui On Leung
Chi Ho Chong
CD22 modulation alleviates amyloid β-induced neuroinflammation
Journal of Neuroinflammation
CD22
Neuroinflammation
Amyloid β
Alzheimer’s disease
title CD22 modulation alleviates amyloid β-induced neuroinflammation
title_full CD22 modulation alleviates amyloid β-induced neuroinflammation
title_fullStr CD22 modulation alleviates amyloid β-induced neuroinflammation
title_full_unstemmed CD22 modulation alleviates amyloid β-induced neuroinflammation
title_short CD22 modulation alleviates amyloid β-induced neuroinflammation
title_sort cd22 modulation alleviates amyloid β induced neuroinflammation
topic CD22
Neuroinflammation
Amyloid β
Alzheimer’s disease
url https://doi.org/10.1186/s12974-025-03361-2
work_keys_str_mv AT yudongmai cd22modulationalleviatesamyloidbinducedneuroinflammation
AT qingqingzhang cd22modulationalleviatesamyloidbinducedneuroinflammation
AT cheuklimfung cd22modulationalleviatesamyloidbinducedneuroinflammation
AT shuionleung cd22modulationalleviatesamyloidbinducedneuroinflammation
AT chihochong cd22modulationalleviatesamyloidbinducedneuroinflammation